CLOs on the Move

Scientia Vascular

www.scientiavascular.com

 
Scientia Vascular offers access devices (microcatheters / guidewires) and therapies that are optimized to address the evolving needs of interventional specialists. Learn more about our next-generation solutions.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Intertek Pharmaceutical Services

Intertek Pharmaceutical Services is a Whitehouse, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABIANT INC

ABIANT INC is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tracon Pharmaceuticals

Tracon Pharmaceuticals, is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The current pipeline takes advantage of established platform technologies to block novel pathways implicated in cancer growth and angiogenesis.

Headstrong Project

Headstrong provides cost-free, barrier-free, stigma-free mental health treatment for veterans and their families.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.